LT - N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (R) ir (S) enantiomerai, kaip IRAK4 inhibitoriai, skirti vėžio gydymui
EN - (R) AND (S) ENANTIOMERS OF N-(5-(3-HYDROXYPYRROLIDIN-1-YL)-2-MORPHOLINOOXAZOLO[4,5-B]PYRIDIN-6-YL)-2-(2-METHYLPYRIDIN-4-YL)OXAZOLE-CARBOXAMIDE AS IRAK4 INHIBITORS FOR THE TREATMENT OF CANCER
Legal status
Patent in force
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
C07D 498/04 |
(2006.01) |
|
|
C07D 513/04 |
(2006.01) |
|
|
C07D 519/00 |
(2006.01) |
|
|
A61K 31/437 |
(2006.01) |
|
|
A61P 1/02 |
(2006.01) |
|
|
A61P 3/00 |
(2006.01) |
|
|
A61P 5/00 |
(2006.01) |
|
|
A61P 7/00 |
(2006.01) |
|
|
A61P 9/00 |
(2006.01) |
|
|
A61P 11/00 |
(2006.01) |
|
|
A61P 13/10 |
(2006.01) |
|
|
A61P 15/00 |
(2006.01) |
|
|
A61P 17/00 |
(2006.01) |
|
|
A61P 19/00 |
(2006.01) |
|
|
A61P 21/00 |
(2006.01) |
|
|
A61P 25/00 |
(2006.01) |
|
|
A61P 27/02 |
(2006.01) |
|
|
A61P 29/00 |
(2006.01) |
|
|
A61P 31/00 |
(2006.01) |
|
|
A61P 35/00 |
(2006.01) |
|
|
A61P 37/02 |
(2006.01) |
European patent
| (11) |
Number of the document |
3805233 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
20211096.1 |
|
Date of filing the European patent application |
2015-01-12 |
| (97) |
Date of publication of the European application |
2021-04-14 |
| (45) |
Date of publication and mention of the grant of the patent |
2024-03-06
|
| (46) |
Date of publication of the claims translation |
2024-05-10
|
Priority applications
| (30) |
Number |
Date |
Country code |
|
158CH2014 |
2014-01-13
|
IN |
|
3000CH2014 |
2014-06-20
|
IN |
Inventors
| (72) |
GUMMADI, Venkateshwar, Rao , IN
SAMAJDAR, Susanta , IN
|
Grantee
| (73) |
Aurigene Oncology Limited ,
39-40 KIADB Industrial Area
Electronic City Phase II
Hosur Road, Bangalore 560100,
IN
|
Attorney or representative
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
Title
| (54) |
N-(5-(3-hidroksipirolidin-1-il)-2-morfolinooksazolo[4,5-b]piridin-6-il)-2-(2- metilpiridin-4-il)oksazol-karboksamido (R) ir (S) enantiomerai, kaip IRAK4 inhibitoriai, skirti vėžio gydymui |
| |
(R) AND (S) ENANTIOMERS OF N-(5-(3-HYDROXYPYRROLIDIN-1-YL)-2-MORPHOLINOOXAZOLO[4,5-B]PYRIDIN-6-YL)-2-(2-METHYLPYRIDIN-4-YL)OXAZOLE-CARBOXAMIDE AS IRAK4 INHIBITORS FOR THE TREATMENT OF CANCER |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-02-18 |
11 |
433.50
EUR
|
Next renewal fee
|
2026-01-12 |
